期刊
ONCOTARGETS AND THERAPY
卷 14, 期 -, 页码 2823-2828出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S294635
关键词
afatinib; leptomeningeal metastasis; EGFR; ALK; co-alterations; lung adenocarcinoma
LM is a severe complication of LAC, and EGFR/ALK co-alterations are rare. Treatment with afatinib led to improved symptoms and reduced lesions in a patient with EGFR and EML4-ALK mutations.
Leptomeningeal metastasis (LM) is a disastrous complication of advanced lung adenocarcinoma (LAC) associated with poor prognosis and rapid deterioration of performance status. The prevalence of epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) co-alterations in patients with LAC was low. Herein, we report a patient with alterations in both EGFR (p. G719A+L747V) and echinoderm microtubule-associated protein-like ALK (EML4-ALK) fusion and LM who was treated with afatinib. The patient's clinical symptoms improved, and imaging examination revealed reduced intracranial and extracranial lesions. The progression-free survival (PFS) using afatinib for LM was 25 months, and no severe adverse events occurred.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据